132 related articles for article (PubMed ID: 36595026)
1. Safety of Crossing Donor-specific Antibodies in Lung Transplantation.
Wang M; Campbell P; Lien DC; Varughese R; Weinkauf J; Nagendran J; Hirji A; Li D; Halloran K
Transplantation; 2023 May; 107(5):1172-1179. PubMed ID: 36595026
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes of Lung Transplantation in the Presence of Donor-Specific Antibodies.
Courtwright AM; Cao S; Wood I; Mallidi HR; Kawasawa J; Moniodis A; Ng J; El-Chemaly S; Goldberg HJ
Ann Am Thorac Soc; 2019 Sep; 16(9):1131-1137. PubMed ID: 31026404
[No Abstract] [Full Text] [Related]
3. Lung transplantation outcomes after crossing low-level donor specific antibodies without planned augmented immunosuppression.
Courtwright AM; Kamoun M; Diamond JM; Kearns J; Ahya VN; Christie JD; Clausen E; Hadjiliadis D; Patel N; Salgado JC; Cevasco M; Cantu EE; Crespo MM; Bermudez CA
Clin Transplant; 2021 Nov; 35(11):e14447. PubMed ID: 34365656
[TBL] [Abstract][Full Text] [Related]
4. Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction.
Iasella CJ; Ensor CR; Marrari M; Mangiola M; Xu Q; Nolley E; Moore CA; Morrell MR; Pilewski JM; Sanchez PG; McDyer JF; Zeevi A
J Heart Lung Transplant; 2020 Dec; 39(12):1417-1425. PubMed ID: 32981841
[TBL] [Abstract][Full Text] [Related]
5. The Presence of Pretransplant HLA Antibodies Does Not Impact the Development of Chronic Lung Allograft Dysfunction or CLAD-Related Death.
Zazueta OE; Preston SE; Moniodis A; Fried S; Kim M; Townsend K; Wood I; Boukedes S; Guleria I; Camp P; El-Chemaly S; Rosas IO; Chandraker A; Milford E; Goldberg HJ
Transplantation; 2017 Sep; 101(9):2207-2212. PubMed ID: 27893614
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
[TBL] [Abstract][Full Text] [Related]
7. Donor-specific and -nonspecific HLA antibodies and outcome post lung transplantation.
Verleden SE; Vanaudenaerde BM; Emonds MP; Van Raemdonck DE; Neyrinck AP; Verleden GM; Vos R
Eur Respir J; 2017 Nov; 50(5):. PubMed ID: 29146602
[TBL] [Abstract][Full Text] [Related]
8. Chronic lung allograft dysfunction is associated with an increased number of non-HLA antibodies.
Xu Q; Elrefaei M; Taupin JL; Hitchman KMK; Hiho S; Gareau AJ; Iasella CJ; Marrari M; Belousova N; Bettinotti M; Narula T; Alvarez F; Sanchez PG; Levvey B; Westall G; Snell G; Levine DJ; Zeevi A; Roux A
J Heart Lung Transplant; 2024 Apr; 43(4):663-672. PubMed ID: 38141896
[TBL] [Abstract][Full Text] [Related]
9. The allograft injury marker CXCL9 determines prognosis of anti-HLA antibodies after lung transplantation.
Shino MY; Zhang Q; Li N; Derhovanessian A; Ramsey A; Saggar R; Britton IN; Amubieya OO; Lari SM; Hickey M; Reed EF; Noble PW; Stripp BR; Fishbein GA; Lynch JP; Ardehali A; Sayah DM; Weigt SS; Belperio JA
Am J Transplant; 2022 Feb; 22(2):565-573. PubMed ID: 34464505
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of antibodies to lung self-antigens (Kα1 tubulin and collagen V) and donor specific antibodies to HLA in lung transplant recipients and implications for lung transplant outcomes: Single center experience.
Rao U; Sharma M; Mohanakumar T; Ahn C; Gao A; Kaza V
Transpl Immunol; 2019 Jun; 54():65-72. PubMed ID: 30794945
[TBL] [Abstract][Full Text] [Related]
11. De Novo DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation.
Tikkanen JM; Singer LG; Kim SJ; Li Y; Binnie M; Chaparro C; Chow CW; Martinu T; Azad S; Keshavjee S; Tinckam K
Am J Respir Crit Care Med; 2016 Sep; 194(5):596-606. PubMed ID: 26967790
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of current strategies for surveillance and management of donor-specific antibodies: Single-center study.
Sullivan D; Ahn C; Gao A; Lacelle C; Torres F; Bollineni S; Banga A; Mullins J; Mohanka M; Ring S; Wait M; Peltz M; Duddupudi P; Surapaneni D; Kaza V
Clin Transplant; 2018 Jul; 32(7):e13285. PubMed ID: 29774598
[TBL] [Abstract][Full Text] [Related]
13. Pre-transplant donor-specific HLA antibodies and risk for poor first-year renal transplant outcomes: results from the Swiss Transplant Cohort Study.
Wehmeier C; Amico P; Sidler D; Wirthmüller U; Hadaya K; Ferrari-Lacraz S; Golshayan D; Aubert V; Schnyder A; Sunic K; Schachtner T; Nilsson J; Schaub S;
Transpl Int; 2021 Dec; 34(12):2755-2768. PubMed ID: 34561920
[TBL] [Abstract][Full Text] [Related]
14. Understanding the Correlation Between DSA, Complement Activation, and Antibody-Mediated Rejection in Heart Transplant Recipients.
Zhang Q; Hickey M; Drogalis-Kim D; Zheng Y; Gjertson D; Cadeiras M; Khuu T; Baas AS; Depasquale EC; Halnon NJ; Perens G; Alejos J; Cruz D; Ali N; Shemin R; Kwon M; Fishbein MC; Ardehali A; Deng M; Reed EF
Transplantation; 2018 Oct; 102(10):e431-e438. PubMed ID: 29916988
[TBL] [Abstract][Full Text] [Related]
15. The fraction of sensitization among lung transplant recipients in a transplant center in Japan.
Kumata S; Hirama T; Watanabe Y; Oishi H; Niikawa H; Akiba M; Tikkanen J; Okada Y
BMC Pulm Med; 2020 Oct; 20(1):256. PubMed ID: 33008353
[TBL] [Abstract][Full Text] [Related]
16. Carfilzomib versus rituximab for treatment of de novo donor-specific antibodies in lung transplant recipients.
Razia D; Hu C; Cherrier L; Nasar A; Walia R; Tokman S
Transpl Immunol; 2022 Dec; 75():101703. PubMed ID: 36049718
[TBL] [Abstract][Full Text] [Related]
17. Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation.
Clerkin KJ; Farr MA; Restaino SW; Zorn E; Latif F; Vasilescu ER; Marboe CC; Colombo PC; Mancini DM
J Heart Lung Transplant; 2017 May; 36(5):540-545. PubMed ID: 27916323
[TBL] [Abstract][Full Text] [Related]
18. Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation.
Lobo LJ; Aris RM; Schmitz J; Neuringer IP
J Heart Lung Transplant; 2013 Jan; 32(1):70-7. PubMed ID: 23260706
[TBL] [Abstract][Full Text] [Related]
19. Use of donor-derived-cell-free DNA as a marker of early allograft injury in primary graft dysfunction (PGD) to predict the risk of chronic lung allograft dysfunction (CLAD).
Keller M; Bush E; Diamond JM; Shah P; Matthew J; Brown AW; Sun J; Timofte I; Kong H; Tunc I; Luikart H; Iacono A; Nathan SD; Khush KK; Orens J; Jang M; Agbor-Enoh S
J Heart Lung Transplant; 2021 Jun; 40(6):488-493. PubMed ID: 33814284
[TBL] [Abstract][Full Text] [Related]
20. Impact of Low-Level Donor-Specific Anti-HLA Antibody on Posttransplant Clinical Outcomes in Kidney Transplant Recipients.
Lee H; Lee H; Eum SH; Ko EJ; Min JW; Oh EJ; Yang CW; Chung BH
Ann Lab Med; 2023 Jul; 43(4):364-374. PubMed ID: 36843405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
